Part 1. Overview Information

Funding opportunities for RFA 25 are contingent upon availability of appropriated funds from the State of Colorado

Funding Opportunity Title:
RFA 25 Cannabis Research Award Opportunity

Funding Opportunity Announcement (FOA) Number:
ICR—RFA-25--001

Funding Opportunity Purpose:
This Funding Opportunity Announcement (FOA) supports projects that will advance the Institute's mission by significantly improving our understanding and advancement of cannabis sciences and their varied impacts.

Mission of the Institute of Cannabis Research (ICR):
The Institute's role and mission are to conduct research related to cannabis, including clinical research, biotechnologies, clinical studies, the efficacies of medical marijuana, and economic development associated with cannabis in Colorado, and to publicly disseminate the results of the research.

Key Dates:
- **RFA Release Date: November 1, 2024**
- **Letter of Intent Open for Submissions: November 15, 2024**, 12:00AM (MST)
- **Letter of Intent Due Date: December 16 , 2024**, 12:00 PM (MST)
- **Review of LOI Submissions: December 17, 2024-January 6, 2025**
- **Applications open for Submissions: January 10, 2025**, 12:00 AM (MST)
- **Application Due Date: February 28, 2025** by 12:00 PM (MST). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- **Anticipated Award Notice Date: May 12-16, 2025**
- **Anticipated Project Start Date: August 1, 2025**

Scientific Merit Review:
Applications will undergo rigorous scientific merit review by a panel of peer subject matter experts.

Institute Review:
Applications that receive the top ratings during the scientific merit review will undergo internal programmatic review by the Institute of Cannabis Research (ICR) Governing Board members and the Director of the ICR. In addition to considering the assessment from the review panels, the Board and Director will consider the proposed project's overall impact on advancing the Institute's mission.

Required Application Instructions:

It is critical that applicants follow the proposal and submission instructions. **A Letter of Intent is required to be eligible for the full proposal submission.** Conformance to all is required and strictly enforced. **Applications that do not comply with these instructions will not be accepted under any circumstances.**

Part 2. Funding Opportunity

Section I. Description

Purpose:

The purpose of this grant program is to fund observational- and hypothesis-based research to include but not limited to scientific, medical, social science, economic, and clinical study of cannabis and other matters that have a significant impact on the state, nation, world, and advance the mission of the ICR. Research to be supported by this opportunity is wide-ranging, and special areas of interest include the following:

- Medical and Clinical Research
- Public Health, Safety, and Harm Reduction
- Pharmacology and Dosing
- Societal Impacts of Cannabis Legislation
- Biology, Chemistry, and Physiology
- Agriculture and Plant Genetics
- Biotechnologies
- Economic Development and Economic Legislation Impact

Section II. Award Information

Application Types Allowed:

The ICR will accept applications that are:

- New application
- Renewal
- Resubmission
- Cannabis Research at Colorado Undergraduate Institutions (CRCUI) Initiative

Funds Available and Anticipated Number of Awards:

The number of awards is contingent upon state funds appropriated for the ICR and the submission of a sufficient number of meritorious applications.

Award Budget:

The ICR anticipates funding 4-6 projects and will depend on the merit, scope, and budget request of applications received. Indirect costs are limited to up to 15% of Modified Total Direct Costs. For this application cycle, the ICR anticipates funding projects with differing annual budget ranges.

Proposed funding ranges (including direct and indirect costs):

- **1-2 projects up to $250,000/yr. up to 3 years**
- **3-4 projects up to $100,000/yr. up to 3 years**

It is incumbent upon the applicants to propose a budget that is both appropriate and well-justified for the proposed project. The budget ranges included above are suggested representative ranges. Applicants may propose annual project budgets that stray outside of the suggested ranges. However, $250,000 is the maximum **annual** project budget allowable under this RFA.

Cannabis Research at Colorado Undergraduate Institutions (CRCUI) Initiative:

The ICR recognizes the value of supporting quality research opportunities at Colorado's undergraduate institutions. In an effort to provide an opportunity for Colorado's Predominantly Undergraduate Institutions to gain an equitable opportunity to secure research funding through the ICR granting program by focusing on these institutions' researcher's strengths and needs, coupled with meritorious and innovative research, through the CRCUI Initiative, which is loosely modeled after the NIH R15 AREA and the NSF RUI opportunities at the federal level. This effort will promote the development of faculty, research scientists, and student researchers in the cannabis field and serve as a pipeline for cannabis researchers to graduate and professional programs.

Award Project Period:

The scope of the proposed project should determine the project period and the project budget. The total project period may not exceed two years and ten months (note: the first performance period will be from August 1 to May 31). For multi-year projects, critical annual reviews will be completed to evaluate whether significant progress is being made in meeting specific aims and warranting continuation of project funding. Please provide consideration in your budget for the ten-month project period of the first year.

Section III. Eligibility Information

1. Eligible Applicants

Organizations:

- Any Colorado Institution of Higher Education and Any Research Entity Associated with an Institution of Higher Education in Colorado
- *CRCUI Eligibility:* Institutions eligible for the CRCUI Initiative are predominantly undergraduate-accredited colleges and universities that award Associate's degrees, Bachelor's degrees, and/or Master's degrees in disciplines supported through this ICR RFA, and have awarded 20 or fewer Ph.D. degrees in disciplines/fields of research potentially supported through this RFA in the two previous academic years combined. The Primary Investigator (PI) must originate from the CRCUI Eligible institution, and that institution must be the primary institution on the application, and ⅔ of the research support must fund research activities at CRCUI Eligible institutions. If you are uncertain of your eligibility, please contact the program officer (dushunte.carmon@csupueblo.edu).
- Any Not-For-Profit Colorado Based Research Entity
- Any Research Entity that has a Marijuana Research and Development License (pursuant to section 44-11-408) and is Conducting the Research with a Colorado Institution of Higher Education.

Eligible Individuals (Principal Investigator):

Any individual with the skills, knowledge, and resources necessary to carry out the proposed research as the Principal Investigator (PI) from an eligible organization is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are encouraged to apply. **It is unlikely that the Institute will award a PI or Co-PI funding for more than one active ICR research project**. For questions about eligibility please contact (csup_icr@csupueblo.edu or dushunte.carmon@csupueblo.edu).

2. Authorization to Conduct Marijuana-Related Research

Under the Drug-Free Schools and Communities Act, Institutions of Higher Education have an obligation to comply with federal drug laws as a condition of receiving grant funding or other financial assistance under any federal program. As a Schedule I substance, it remains illegal under federal law to import, manufacture, distribute, possess, or use marijuana. However, federal law provides the Food and Drug Administration (FDA) with the ability to approve research using Schedule I controlled substances. The following guidance may apply to applicants depending upon the nature of the proposed study and the type and funding status of the applicant organization. **Principal investigators should also review this guidance with their organization's legal counsel to determine its applicability.** The IRC only supports research that abides by federal standards. Projects that do not strictly adhere to the federal rules as described by the DEA and adhere to federal human research regulations will not be funded by the ICR, see: https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-057)(EO-DEA217)_Researchers_Manual_Final_signed.pdf

Human Clinical Trials/Clinical Studies:

Under federal law, a researcher who wishes to administer marijuana (cannabis containing > 0.3% total THC) or its component parts to human subjects must (as applicable per the study details):

- Submit an Investigational New Drug application to the FDA.
- Obtain a registration from the Drug Enforcement Administration (DEA)
- Obtain approval from the appropriate Institutional Review Board (IRB)
- Receive a determination from the U.S. Department of Health and Human Services that the investigator is qualified, and the proposed research has merit.
- Acquire the marijuana from the National Institute on Drug Abuse's approved source.
- Follow DEA regulations and guidelines for storage and prescription.
  Note: Hemp (cannabis containing < 0.3% total THC) does not fall under these restrictions

Human Observational Studies:

These are studies in which subjects marijuana (cannabis containing > 0.3% total THC) or its component parts, but the researcher does NOT procure it for the subjects, the marijuana/component parts is not consumed on the institution's campus. For these types of studies, the researcher must (as applicable per the study details):

- Obtain approval from the appropriate IRB

Animal Studies:

Under federal law, a researcher who wishes to use marijuana (cannabis containing > 0.3% total THC) or its component parts for research involving animals must (as applicable per the study details):

- Obtain approval from the appropriate Institutional Animal Care and Use Committee (IACUC). No Funds will be released before proof of this approval is provided to the ICR.
- Obtain a registration from the DEA.
- Acquire the marijuana from the NIDA approved source.
- Follow DEA regulations and guidelines for storage and prescription.
  Note: Hemp (cannabis containing < 0.3% total THC) does not fall under these restrictions

Basic Research:
Under federal law, a researcher who wishes to use marijuana (cannabis containing > 0.3% total THC) or its component parts for research that does not involve human subjects or animals, yet is directed toward greater knowledge or understanding of the fundamental aspects of marijuana must (as applicable per the study details):

- Obtain a registration from the DEA
- Acquire the marijuana from the NIDA-approved source.
- Follow DEA regulations and guidelines for storage and prescription
- Testing of marijuana or its component parts for chemical composition and potency by a state-certified Colorado laboratory or another laboratory meeting similar quality standards and qualifications is **strongly recommended** as part of clinical trials, observational studies (in which the study subjects procure their own marijuana or component parts), or animal studies involving the administration of marijuana or its component parts.
- Testing of blood, serum, or plasma levels of cannabinoids is **recommended as part of clinical studies** and should be performed by a College of American Pathologists (CAP) accredited laboratory with an appropriately sensitive, specific, and validated assay using methodology such as high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS).
  Note: Hemp (cannabis containing < 0.3% total THC) does not fall under these restrictions.

Drug Studies:

- Study drugs may be donated by pharmaceutical manufacturers; however, study results may not be used in any submission to a regulatory authority as part of a product approval, except to the extent the manufacturer is required by law or regulation to include in such a submission safety data relating to the use of the study drug.
- With marijuana being a Schedule I substance, it remains illegal under federal law to import, manufacture, distribute, possess, or use marijuana. However, federal law provides the Food and Drug Administration (FDA) with the ability to approve research using Schedule I controlled substances.

Section IV. Application and Submission Information

1. Content and Form of Application Submission

Applications that are out of compliance with these instructions will not be accepted for review.

Page Formatting Requirements

- 11 point font, Arial or Times New Roman
- Single spacing
- 0.5 inch margins
- Include page numbers
- All attachments must be submitted in PDF format
- Name all Files “PI Surname, Document Name”

Page Limitations

All page limitations described in the Table of Page Limits Below:

Document Name	Page Limit	Notes
Biographical Sketch	**2**	Use Biosketch Template; 2-page limit is per each respective biographical sketch
Project Summary or Abstract	**N/A**	No more than 500 words using application form field
Research Strategy including References	**6**	The Research Strategy must address each section clearly and concisely and include all the required information for the section. a. Significance / Introduction to Problem / Project i. Clearly describe the problem that your project proposes to address and explain why the proposed research is important and significant for Colorado. ii. Clearly indicate how the proposed research advances the mission of the ICR. iii. Summarize the relevant scientific literature that clearly justifies the appropriateness of conducting the proposed research and the gap in the field that will be filled. b. Hypothesis aims and methodology. Explain the primary hypothesis goal or study ii. State the specific aims and methodology to achieve each aim. c. Summary of anticipated results. i. Explain the possible outcomes of the study and the significance of each. ii. Identify any pitfalls in the research design and how they would be addressed. d. References cited. i. Provide a complete list of references cited within the text and at the end of the document. The References section at the end of the Research Strategy will not count towards the six-page limit.

Document Name	Page Limit	Notes
Detailed Budget	**N/A**	The combined total budget (direct and indirect costs) may not exceed the following per project year: $250,000, or $100,000 for smaller projects. See the proposed budget schedule under (Award Budget). Expenses need to reflect the actual needs of the proposed project. a. Please provide a detailed budget using the budget template provided. b. Do not modify the format of the spreadsheet (budget template). The budget must describe all expenses included. Please send in the budget through an Excel file only. c. Applicants are responsible for ensuring the calculations in the budget are accurate. d. Detailed subcontractor budgets must be provided using the original template, as well as separate copies of the same budget template (Page 2 of the budget template). e. ICR reserves the right to deny requests for any item listed in the budget that is deemed to be unnecessary for the implementation of the project. f. Unallowable expenses: Funds from this grant may NOT be used for Capital construction, building renovations (without prior approval from ICR), lobbying, and conference attendance unless it is for scientific presentation. regarding the funded study (international travel, except to Canada, will NOT be supported), cell phones. **Indirect Rate: Indirect Costs are limited up to 15% of Modified Total Direct Costs. For applicants that do not have a federally negotiated rate agreement, please use the minimum rate of 10%.**

Document Name	Page Limit	Notes
Budget Justification	**4**	Applicants are required to justify each line item requested. The NIH format is suggested.
Dissemination Activities	**2**	The Institute of Cannabis Research grant projects are expected to yield a product. Please describe the planned final product(s) that will be derived from the support provided through the requested grant period. Please include all available information/details (e.g., targeted journal and expected submission timeline, funding agency and program, exhibition information, or performance timeline). All proposals must demonstrate deliverables for each year of funding. If the PI has been previously funded by the ICR please provide a summary of products delivered to date. As a condition of accepting funding the PI(s) are required by HB19-1311 to present the results of the funded project at the ICR's annual symposium no later than the symposium occurring the year after the research project has ended. **As a condition of accepting funding the PI(s) are required (HB19-1311) to present the results of the funded project at the ICR's annual symposium no later than the symposium occurring the year after the research project has ended.**
Career Development	**1**	The career development section is the acknowledgment of students both undergraduate and graduate who will contribute to the project. Please state how many students you intend to use on the project, what their classification is graduate or undergraduate), and how each proposed student will contribute to the project.

Facilities and Other Resources	**2**	Please state all of the sites where the proposed project will be conducted. The sites will consist of all locations in which the PI and the Co PIs will use to work on their proposed research. The PI also needs to state what types of equipment or instrumentation they will use that will have an impact on the project.

2. Compliance Review Boards

The selected awardees will be responsible for submitting a copy of the proposal to the appropriate Review Board and confirmation of approval must be submitted to the ICR prior to the release of research funds.

- Research involving human subjects must be reviewed and approved by the Institutional Review Board (IRB, Human Subjects Committee);
- Research involving animal subjects must be reviewed and approved by the Institutional Animal Care and Use Committee (IACUC);
- Research involving recombinant DNA or hazardous materials must be reviewed and approved by the Institutional Biosafety Committee.
- PI is responsible for submission to any Other Institutional Review Boards required by their home institution.

3. Funding Restrictions

All ICR awards are subject to the terms and conditions, cost principles, and other considerations described in this document as well as the ICR Award Policies.

Section V. Application Review Information

1. Criteria:

- Only the review criteria described below will be considered in the review process. As part of the ICR mission, all applications submitted to the ICR are evaluated for scientific and technical merit through the ICR peer review system. Proposals will be reviewed and evaluated by a selection of peer reviewers appointed by the ICR.. Proposal evaluations will be completed using a scoring rubric. Top scoring proposals will be reviewed and evaluated by ICR Governing Board members (excluding those with a conflict of interest) with recommendations sent to the ICR Director.
- A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

I. Overall Impact:

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

II. Significance:

Does the project address an important scientific problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? Do the investigator(s) have appropriate experience and training? Have the investigator(s) demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise? Is there a direct and positive impact that fulfills a research need for the people of Colorado?

III. Innovation:

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

IV. Approach:

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility, and will particularly risky aspects be managed?

V. Broader Impacts:

How well does the activity advance discovery and understanding while promoting teaching, training, and learning? How well does the proposed activity broaden the participation of underrepresented groups (e.g., gender, ethnicity, disability, geographic, etc.)? To what extent will it enhance the infrastructure for research and education, such as facilities, instrumentation, networks, and partnerships?

VI. Environment:

Will the results be disseminated broadly to enhance scientific and technological understanding? What may be the benefits of the proposed activity to society? Will the scientific environment in which the work will be done contribute to the probability of success? Is there institutional support, equipment, and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? Are planned analyses and statistical approaches appropriate for the proposed study design and methods used to assign participants and deliver interventions?

VII. Data Analysis:

Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

VIII. Clinical Research:

If the project involves human subjects and/or ICR-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed? For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials. For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate 1) the justification for the exemption,
2) human subjects' involvement and characteristics, and 3) sources of materials. When the proposed project involves human subjects and/or ICR-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed.

IX. Animal Research:

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) the justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals.

X. Biohazards:

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

XI. Budget:

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

XII. Clinical Trials:

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms?

1. **For trials focusing on clinical or public health endpoints**, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy?

2. **For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial Clinical Trials needed to advance scientific understanding?** Investigator(s)? Are the PD(s)/PI(s), collaborators, and other researchers well-suited to the project? Do the investigator(s) have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance, and organizational structure appropriate for the project? With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage, and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management, and statistics?

3. **For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?** Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information, or potential to advance scientific knowledge or clinical practice? Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative, and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, and demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified? Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment

timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria have been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity? Are the plans to standardize, assure quality of, and monitor adherence to the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain the required study agent(s)? Does the application propose to use existing available resources, as applicable? If proposed, are the administrative, data coordinating, enrollment, and laboratory/testing centers appropriate for the trial proposed? Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate? If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial? If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and (4) operate within the proposed organizational structure? Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative databases, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate? Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?

Section VI. Award Administration Information - Please find the details of Section VI in the Supporting Document named ICRFundingAnnouncmentRFA25

1. Award Notices:

A formal notification in the form of an award letter will be provided to the applicant organization for successful applications. The award letter will be signed by an ICR Official as the authorizing document and will be sent via email to the PI and grantee's business official/AOR.

Any application awarded in response to this FOA will be subject to terms and conditions found on the ICR website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

2. Reporting

When multiple years are involved, awardees will be required to submit an Interim Progress Report (IPR) annually as outlined in the terms and conditions in the Award Letter. A Final Progress Report (FPR) will be required within 90 days of the terminal end date of an award as outlined in the terms and conditions of the Award Letter.

Section VII. ICR Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. All questions should be submitted to the ICR program staff at csup_icr@csupueblo.edu.

APPLICATION DOCUMENT CHECKLIST

[ ] Letter of Intent (previously submitted) [ ]

Biographical Sketch (ICR Template)

[ ] Project Summary or Abstract (Field completed; no more than 500 words) [ ]

Research Strategy including References (6-page limit + References)

[ ] Detailed Budget (ICR Budget Template)

[ ] Budget Justification (NIH Format Suggested) [ ]

Dissemination Activities

[ ] Career Development (If Applicable) [ ]

Facilities and Other Resources

[ ] Letters of Support (Not Required)

[ ] Human Subjects and Clinical Trials Information (If Applicable)